Skip to content

In the BioHarmony Drug Report Database

Satralizumab

Enspryng (satralizumab) is an antibody pharmaceutical. Satralizumab was first approved as Enspryng on 2020-08-14. It is used to treat neuromyelitis optica in the USA. It has been approved in Europe to treat neuromyelitis optica.
Trade Name Enspryng
Common Name Satralizumab
Indication neuromyelitis optica
Drug Class Monoclonal antibodies: humanized, immunomodulating
Satralizumab
Get full access now